431 related articles for article (PubMed ID: 36883630)
21. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
22. Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments.
Carrero I; Liu HC; Sikora AG; Milosavljevic A
Oncogene; 2019 May; 38(19):3551-3568. PubMed ID: 30655605
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
24. Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC.
Gong X; Xiong J; Gong Y; Zhang J; Zhang J; Yang G; Chi H; Tian G
Front Immunol; 2023; 14():1275270. PubMed ID: 37876923
[TBL] [Abstract][Full Text] [Related]
25. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
Li J; Tang LL; Ma J
BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
[TBL] [Abstract][Full Text] [Related]
26. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive profile of TCF1
Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
[TBL] [Abstract][Full Text] [Related]
28. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
[TBL] [Abstract][Full Text] [Related]
29. Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.
Bao J; Betzler AC; Hess J; Brunner C
Front Immunol; 2023; 14():1233085. PubMed ID: 37868967
[TBL] [Abstract][Full Text] [Related]
30. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
[TBL] [Abstract][Full Text] [Related]
31. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
32. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of B lymphocyte infiltration in HPV
Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
36. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
[TBL] [Abstract][Full Text] [Related]
37. Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma.
Nakamura S; Ohuchida K; Hayashi M; Katayama N; Tsutsumi C; Yamada Y; Hisano K; Okuda S; Ohtsubo Y; Iwamoto C; Torata N; Mizuuchi Y; Shindo K; Nakata K; Moriyama T; Morisaki T; Oda Y; Nakamura M
Br J Cancer; 2023 Oct; 129(8):1314-1326. PubMed ID: 37604932
[TBL] [Abstract][Full Text] [Related]
38. Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
Qureshi HA; Zhu X; Yang GH; Steadele M; Pierce RH; Futran ND; Lee SM; Méndez E; Houghton AM
Oral Oncol; 2022 Apr; 127():105774. PubMed ID: 35219073
[TBL] [Abstract][Full Text] [Related]
39. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis.
Galvis MM; Borges GA; Oliveira TB; Toledo IP; Castilho RM; Guerra ENS; Kowalski LP; Squarize CH
Crit Rev Oncol Hematol; 2020 Jun; 150():102966. PubMed ID: 32371338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
